(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 11.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 301.81%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.45%.
Niagen Bioscience's revenue in 2025 is $124,709,000.On average, 7 Wall Street analysts forecast NAGE's revenue for 2025 to be $10,294,193,870, with the lowest NAGE revenue forecast at $9,823,337,650, and the highest NAGE revenue forecast at $10,692,426,503. On average, 6 Wall Street analysts forecast NAGE's revenue for 2026 to be $12,409,854,615, with the lowest NAGE revenue forecast at $11,618,975,777, and the highest NAGE revenue forecast at $13,239,838,460.
In 2027, NAGE is forecast to generate $14,640,436,200 in revenue, with the lowest revenue forecast at $13,867,114,713 and the highest revenue forecast at $15,284,471,741.